Ind-Swift Laboratories is currently trading at Rs. 60.00, up by 8.05 points or 15.50% from its previous closing of Rs. 51.95 on the BSE.
The scrip opened at Rs. 52.05 and has touched a high and low of Rs 60.75 and Rs 51.30 respectively. So far 815323 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 133.00 on 08-Feb-2012 and a 52 week low of Rs 39.10 on 14-Aug-2012.
Last one week high and low of the scrip stood at Rs 52.90 and Rs 46.20 respectively. The current market cap of the company is Rs. 233.66 crore.
The promoters holding in the company stood at 50.58% while Institutions and Non-Institutions held 4.20% and 45.16% respectively.
Ind-Swift Laboratories proposal for restructuring of the company’s debt has been approved by the Empowered Group of Corporate Debt Restructuring (CDR) Cell communicated vide its letter of approval (LOA) dated November 09, 2012.
Pursuant to the term and conditions of LOA, the master restructuring agreement (MRA) has been executed between the company and the lenders on December 27, 2012. The cut off date for the CDR Package shall be July 01, 2012.
The CDR Package envisages reduction in rate of interest; deferment of payment of interest and principal amount of working capital facilities and term loans after a moratorium of 21 months from the cut off date.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API). The company’s business model is focused on domestic market and high-value mature regulated markets along with considerable focus on the emerging markets as well.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1522.40 |
Dr. Reddys Lab | 6405.75 |
Cipla | 1482.00 |
Zydus Lifesciences | 1074.35 |
Lupin | 1625.00 |
View more.. |